NFKB1 and Parkinson disease: To bridge identity → content → function, MFH products intended for PD research should adopt mechanism-linked release assays (e.g., Nrf2/ARE reporter activation, NF-κB nuclear-translocation inhibition in microglia, protection of human iPSC-derived TH+ neurons under oxidative stress) in addition to pharmacopeial quality tests (see Table 4 in the main text).